Ex vivo cytokine activation of peripheral blood stem cells: A potential role for adoptive cellular immunotherapy

Journal of Hematotherapy and Stem Cell Research

Volumn 10, Issue 2, 2001, Pages 283-290

  Meehan, K R ^a   Wu, A ^a   Hassan, R ^a   Miao, Y ^a   Chawla, J ^a   Slack, R ^a   Gehan, E ^a   Herscowitz, H B ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CHROMIUM 51; CYTOKINE; INTERLEUKIN 12; INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; APHERESIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL STIMULATION; CELL STRAIN MCF 7; CHROMIUM 51 RELEASE; CLONOGENIC ASSAY; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOTOXICITY; EFFECTOR CELL; HUMAN; HUMAN CELL; MONONUCLEAR CELL; NATURAL KILLER CELL; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

BLOOD COMPONENT REMOVAL; BONE MARROW CELLS; BREAST NEOPLASMS; CELL SURVIVAL; CELLS, CULTURED; COLONY-FORMING UNITS ASSAY; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE I, RECOMBINANT; INTERLEUKIN-12; INTERLEUKIN-2; LYMPHOCYTES; RECOMBINANT PROTEINS; TUMOR CELLS, CULTURED;

EID: 0035018739     PISSN: 15258165     EISSN: None     Source Type: Journal    
DOI: 10.1089/15258160151135006     Document Type: Article

References (30)

1. Potent graft anti-tumor effect in natural killer-resistant disseminated tumors by transplantation of interleukin-2 activated syngeneic bone marrow in mice
2. Interleukin-2 activation of chemotherapy and growth factor-mobilized peripheral blood stem cells for generation of cytotoxic effectors
3. Bone marrow transplantation with interleukin-2 activated bone marrow followed by interleukin-2 therapy for acute myeloid leukemia in mice
4. Immunotherapy with interleukin-2 and alpha-interferon following IL-2 activated hematopoietic stem cell transplantation for breast cancer
5. Stem cell transplantation with chemoradiotherapy myeloablation and interleukin-2
6. Interleukin-2 with or without lymphokine-activated lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia
7. Long-term growth of lymphokine-activated killer (LAK) cells: Role of anti CD-3, beta-IL-1, interferon-gamma and -beta
8. IL-4-induced lymphokine activated killer cells: Lyric activity is mediated by phenotypically distinct natural-killer-like and T-cell-like large granular lymphocytes
9. + natural killer cells. A comparative study
10. Generation of activated killer (AK) cells by recombinant interleukin-2 (IL-2) in collaboration with interferon-gamma (IFN-gamma)
11. Effect of granulocyte-macrophage colony-stimulating factor on lymphokine-activated killer cell induction
12. Interleukin-12 (IL-12) alone or in synergistic combination with IL-2 for in vitro activation of human bone marrow: Differential effects at different time points
13. Interaction of various cytokines with interleukin-2 on the generation of killer cells from human bone marrow: Application in purging of leukemia
14. One-way layout: Multiple comparison
15. One-way classifications: Analysis of variance
16. The stimulatory effects of interleukin (IL)-12 on hematopoiesis antagonized by IL-12-induced interferon gamma in vivo
17. Interleukin-12-induced interferon-gamma inhibits hematopoiesis in vivo in mice
18. Dual stimulatory and inhibitory effect of NK cell stimulating factor/IL-12 on human hematopoiesis
19. Interleukin-2: Inception, impact and implications
20. Cytotoxic lymphocyte maturation factor (interleukin-12) is a synergistic growth factor for hematopoietic stem cells
21. Interleukin-12 augments cytolytic activity of peripheral blood lymphocyte from patients with hematologic and solid malignancies
22. + T cells closely correlates with CD56 surface expression
23. Generation of cytokine-induced killer cells using exogenous interleukin-2, -7 or -12
24. + killer cells
25. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor
26. Interleukin-2 activation of human bone marrow in long-term cultures: An effective strategy for purging and generation of anti-tumor cytotoxic effectors
27. Interleukin-2 activated hematopoietic stem cell transplantation for breast cancer: Investigation of dose level with clinical correlates
28. A multicenter phase I trial using STAMP V (CTCb) with IL-2 activated PBSC and IL-2 post transplantation for women with high-risk breast cancer
29. Gene-marking to trace the origin of relapse after autologous bone marrow transplantation
30. Immunotherapy with interleukin-2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma. A feasibility trial